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ABSTRACT
Estradiol and Daily Affective Experiences in Trauma-Exposed Women
by
Jenna K Rieder
Advisor: Mariann R Weierich PhD

People who experience trauma can develop enduring trauma-related symptoms. In daily
life, post-trauma symptoms (e.g., elevated physiological arousal) can be triggered by affectively
salient cues in the environment, especially by cues that act as trauma reminders. Trauma
exposure is associated with enduring changes in two biological stress systems: the sympathetic
nervous system (SNS) and the hypothalamic-pituitary-adrenal (HPA) axis. In women, activity in
both systems is additionally modulated by fluctuations in levels of sex hormones (e.g., estradiol),
which could influence physiological responses to trauma reminders. Additionally, previous work
has linked the sex hormone estradiol with affect, suggesting that menstrual cycle might influence
trauma-related symptoms or daily affect more broadly within the context of trauma exposure.
However, we do not yet have a clear understanding of how estradiol influences affective
experiences post-trauma.
We used a multi-method approach to examine the influence of estradiol on daily affective
experiences in a non-clinical, trauma-exposed sample of 40 naturally cycling premenopausal
women. The first specific goal of this study was to test the hypothesis that low estradiol would be
related to trauma symptoms, including an asymmetrical profile of SNS and HPA axis stress
reactivity to a naturalistic trauma reminder. Lower estradiol was related to greater number and
severity of PTSD symptoms, and participants in low versus high estradiol menstrual cycle phases
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showed higher SNS and reduced HPA axis reactivity to a trauma reminder. These results suggest
that lower estradiol is associated with a less adaptive profile of stress system reactivity and
increased PTSD symptom expression.
The second specific goal of this study was to test the influence of menstrual cycle phase
on daily affect in a subset of 30 participants. We assessed affective experience over the course of
a 10-day ecological momentary assessment (EMA) period, which included the early follicular
(low estradiol) and late follicular (high estradiol) phases. We selected these menstrual cycle
phases to capture a portion of the cycle where estradiol increased, whereas progesterone
remained low, allowing us to test the effects of estradiol without the confound of progesterone.
Participants reported more frequent aversive affective experiences, defined as negatively
valenced, high arousal states, including PTSD symptoms, during the early versus late follicular
phase. During the early versus late follicular phase, participants also reported greater negative
and positive affect and showed greater variability in affective ratings. These results suggest that
lower estradiol menstrual cycle phases are characterized by more frequent aversive affective
experiences, greater affective lability and increased PTSD symptom severity.
Together, these results have potential implications for clinical assessment, as menstrual
cycle phase at the time of assessment could influence diagnosis of PTSD or symptom severity.
Additionally, clinicians working with women with PTSD might anticipate greater affective
lability and increased symptom severity during low estradiol phases of the menstrual cycle.
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1. Introduction
In the U.S., more than half of the population will experience a traumatic event at some point
in their lives (e.g., Kessler et al., 2005), and some will develop enduring symptoms of post-traumatic
stress disorder (PTSD). Trauma is an event in which a person experiences a threat or perceived threat
to his/her life or physical integrity or that of another person, especially a close other (American
Psychiatric Association, 2013). Hallmark PTSD symptoms include re-experiencing of the traumatic
event through intrusive thoughts and memories, nightmares or flashbacks. In addition to reexperiencing symptoms, there are three other DSM-5 symptom clusters: avoidance, negative
alterations in cognitions and affect and arousal symptoms. Avoidance symptoms include active
cognitive avoidance of trauma-related memories or thoughts and behavioral avoidance of people,
places or situations associated with the event. Negative alterations in cognition and affect include
negative cognitions (e.g., inappropriate self-blame, strongly negative beliefs about oneself, other
people or the world), increased negative affect and reduced positive affect. Finally, arousal
symptoms include heightened physiological arousal, tonically and in response to stressors, irritability
or angry outbursts, risky behaviors and hypervigilance for threat even in safe environments. All of
these PTSD symptoms can lead to considerable subjective distress and functional impairment for
trauma-exposed people.
In daily life, PTSD symptoms can be triggered by exposure to affectively salient cues in the
environment, especially by cues that act as trauma reminders. In women, stress reactivity and
negative affect vary according to menstrual cycle phase, and fluctuations in female sex hormones
(e.g., estradiol) might influence trauma-related symptoms. However, despite these potential effects of
hormone fluctuations on PTSD symptoms, we do not yet have a clear understanding of the relation
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between steroid sex hormones and daily affective experiences within the context of trauma exposure.
This knowledge could potentially inform more effective treatments for trauma-exposed women.
Most prior PTSD research has focused on men, and most studies that included women have
not controlled for hormonal status or menstrual cycle phase. Compounding the imbalance, animal
models of PTSD have often excluded females to avoid the potential confounds posed by estrous
cycle variation. Thus, the role of fluctuations of female sex hormones on PTSD symptoms is poorly
understood. It is important to address this disparity, given that women are twice as likely to develop
PTSD following trauma than men (e.g., Breslau, 2002; Haskell et al., 2010; Perrin et al., 2014) and
typically experience more severe (e.g., Seedat, Stein, & Carey, 2005) and persistent (e.g., Holbrook,
Hoyt, Stein, & Sieber, 2002) symptoms. Although men and women differ in rates of exposure to
different types of trauma, women’s increased risk for PTSD persists in studies controlling for trauma
type (Tolin & Foa, 2006) and has been reported across cultures (Altemus, 2006), suggesting that
societal factors alone cannot explain increased risk. Learning more about physiological processes
unique to women that might contribute to differential vulnerability for post-trauma symptoms could
enhance preventative therapeutic strategies for trauma-exposed women. Research in this area could
also inform treatment tailoring for women with PTSD through the identification of hormone changes
associated with greater vulnerability for clinical symptoms.
One potential risk factor for increased symptoms in women is fluctuations in gonadal
hormones. In particular, estradiol (17β-estradiol), the most prevalent and biologically potent
estrogen in non-pregnant premenopausal women, is broadly associated with affective responses, and
estradiol fluctuations might increase risk for aversive affective experiences. Throughout the lifespan,
dramatic changes in circulating estradiol levels are associated with changes in affect (e.g., Hickey,
Bryant, & Judd, 2012), and risk for affective disorders increases when estradiol steeply declines
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during the perimenopause, menopause and postpartum periods (e.g., Callegari et al., 2007; Freeman,
Sammel, Lin, & Nelson, 2006; Vesga-Lopez et al., 2008). Among women treated for clinical
symptoms of affective disorders during these hormonal transitions, pharmacological treatment with
estrogens has been shown to augment treatment outcomes (e.g., Sichel, Cohen, Robertson,
Ruttenberg, & Rosenbaum, 1995; Soares, Almeida, Joffe, & Cohen, 2001).
In naturally cycling, premenopausal women, circulating estradiol fluctuates more gradually
across the menstrual cycle, and these fluctuations might predict patterns of daily affect, including risk
for affective symptoms. The menstrual cycle consists of two main phases: the follicular phase, which
spans menses to ovulation, and the luteal phase, which begins after ovulation and lasts until the end
of the cycle. The follicular phase is characterized by changes in estradiol, whereas the luteal phase is
characterized by changes in estradiol and progesterone.
Fluctuations in gonadal hormones over the course of a typical menstrual cycle are shown in
Figure 1. At the beginning of the menstrual cycle, during the early follicular phase, levels of estradiol
and progesterone are low. During the late follicular phase, estradiol rises and comes to a peak, then
declines following ovulation. Estradiol levels again increase from the early to mid-luteal phase, when
they reach a secondary peak, and then decline during the late luteal phase. However, the luteal phase
is also characterized by changes in progesterone. Progesterone starts to increase during the early
luteal phase, peaks during the mid-luteal phase and declines during the late luteal phase. Menstrual
cycle variation has been associated with changes in affect, but we do not yet have a clear
understanding of how gonadal hormone fluctuations influence post-trauma symptoms.
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Figure 1. Cyclic variation in steroid sex

Estradiol impacts activation of neural affective circuitry
Among premenopausal women, normative individual differences in estradiol are broadly
associated with affect. For example, lower estradiol is associated with higher trait emotional
reactivity (e.g., Ziomkiewicz, Wichary, Bochenek, Pawlowski, & Jasienska, 2012). Consistent with
self-report measures, lower estradiol is associated with heightened activation in affective brain areas
(e.g., amygdala) and reduced activation in prefrontal regulatory areas during affective processing
(e.g., Zeidan et al., 2011), which together fit a characteristic neural profile of elevated stress and
anxiety states. In addition to individual differences, premenopausal women also experience
fluctuations in affect across the menstrual cycle, with greater negative affect (e.g., anxiety, depressed
mood) generally reported during lower estradiol menstrual cycle phases (e.g., Gonda et al., 2008).
Maladaptive stress reactivity is one aspect of affective responding that might increase distress
during low estradiol phases of the menstrual cycle. Previous studies have demonstrated menstrual
cycle variation in functional activation of the stress response circuitry that underlies the
neuroendocrine stress response. Compared to women in the late follicular phase (high estradiol),
women in the early follicular phase (low estradiol) show greater recruitment of the stress
response circuitry (e.g., central amygdala, paraventricular and ventromedial hypothalamic nuclei,
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brainstem nuclei, orbitofrontal cortex) during aversive image processing (e.g., Goldstein et al.,
2005; Jacobs et al., 2014). Additionally, in one study, women in the early follicular versus late
follicular phase show greater hippocampal deactivation in response to a psychological stressor
along with greater self-reported distress (e.g., Albert, Pruessner, & Newhouse, 2015). Sustained
hippocampal activity is thought to reflect intact regulation of the stress response (e.g., Pruessner
et al., 2010), whereas greater stress-related hippocampal deactivation during lower estradiol
states might index greater vulnerability to stress-related symptoms.

Two distinct systems contribute to the stress response
Stressful events or situations elicit activity in two physiological stress systems: the
sympathetic nervous system (SNS) and the hypothalamic-pituitary-adrenal (HPA) axis, which
contribute to different components of the stress response (see Figure 2). SNS activity underlies
immediate responses to stressors, commonly referred to as the fight or flight response. The SNS
response is initiated by increased activity of the norepinephrine-producing neurons of the locus
coeruleus in the brainstem, and increased norepinephrine signaling spreads to affective brain areas
(e.g., amygdala) (Pickel, Segal, & Bloom, 1974). Some of these projections exit the central nervous
system through spinal nerves and affect a variety of organ systems via postganglionic sympathetic
nerve fibers. SNS activity generates rapid physiological changes (e.g., increased heart rate, faster
breathing, release of norepinephrine and epinephrine) that enable an organism to cope with an
imminent stressor (Chrousos & Gold, 1992, for review). Following the SNS, a second response is
initiated by the HPA axis, which underlies a slower, but more sustained response to stressors.
Activity along the HPA axis is initiated by the hypothalamus, which communicates with the pituitary
gland, enacting a hormonal cascade that ultimately triggers the release of the well-known stress
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hormone cortisol from the adrenal glands. In response to a stressor, the hypothalamus releases
corticotropin-releasing hormone (CRH) onto the anterior pituitary gland, which in turn releases
adrenocorticotropic hormone (ACTH). ACTH released into the bloodstream travels to the adrenal
glands, which release cortisol (e.g., Tsigos & Chrousos, 1994). In contrast to norepinephrine, whose
levels peak within a few minutes of stressor onset, cortisol levels peak approximately 30 minutes
post-stressor onset (Kirschbaum & Hellhammer, 2000).
Successful coordination of sympathetic and HPA axis activity is adaptive in the face of actual
threats, whereas heightened or inappropriate activation of these systems can become maladaptive.
Measurement of activity in these stress systems using peripheral biomarkers has allowed researchers
to learn more about individual variation in stress reactivity and its relation to psychological
functioning. Activity in both systems can be measured non-invasively and cost-effectively in saliva
samples using commercially available immunoassay kits. Measurement has to date mostly included
salivary cortisol, a well-established index of HPA axis function. More recently, the digestive enzyme
salivary alpha amylase (AA) has emerged as a surrogate marker of SNS activity, as salivary glands
increase production of AA in response to increased noradrenergic signaling (e.g., Chatterton,
Vogelsong, Lu, Ellman, & Hudgens, 1996). AA levels reliably increase in response to a variety of
laboratory psychological stressors (e.g., Nater & Rohleder, 2009; Schumacher, Kirschbaum, Fydrich,
& Ströhle, 2013).
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Figure 2. Two physiological systems underlie the stress response (adapted from Eisenberger &
Cole, 2002). The sympathetic nervous system (SNS; right) provides a nearly immediate response
to stressors. SNS activation is followed by activation of the hypothalamic-pituitary-adrenal
(HPA) axis (left).

Previous studies of SNS and HPA axis function have shown that activity in these systems is
influenced by sex and by trauma history, although the interaction of these factors is not yet
understood. Women show lower HPA reactivity to laboratory psychosocial stressors than men
(e.g., Kajantie & Phillips, 2006; Uhart, Chong, Oswald, Lin, & Wand, 2006), although this effect
varies by menstrual cycle phase, with relatively high HPA responses (equivalent to those of men)
observed in women during the mid-luteal (higher estradiol) phase (Kirschbaum, Kudielka, Gaab,
Schommer, & Hellhammer, 1999). The few studies of sex differences in AA reactivity to
psychological or physiological stress tasks (e.g., Schoofs, Hartmann, & Wolf, 2008; van
Stegeren, Wolf, & Kindt, 2008) suggest no overall differences in reactivity, although estrogens
are known to increase parasympathetic tone, resulting in lower SNS activity at rest in
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premenopausal women (e.g., Conte, 2003). In general, however, stress reactivity also varies as a
function of gonadal hormone status and menstrual cycle phase.
Stress reactivity differs not only by sex, but also by trauma history. Trauma exposure is
usually associated with heightened sympathetic reactivity to aversive or trauma-related stimuli (e.g.,
Ali & Pruessner, 2012; McTeague et al., 2010). Trauma is also associated with changes in HPA axis
reactivity to laboratory stressors, although the results are mixed, with heightened reactivity reported
in some studies (e.g., Bremner et al., 2003; Inslicht et al., 2006) and blunted reactivity in other studies
(e.g., Carpenter, Shattuck, Tyrka, Geracioti, & Price, 2011; Elzinga et al., 2008). The inconsistencies
in the evidence suggest that additional variables might influence the relationship between trauma
and stress reactivity. Steroid sex hormones such as estradiol might be one such factor, especially
given that blunting of the HPA axis is more frequently observed in women (e.g., Meewisse,
Reitsma, De Vries, Gersons, & Olff, 2007). Additionally, there are overlapping adrenal and
gonadal steroid hormone receptors in areas of the stress response circuitry (e.g., paraventricular
nucleus, amygdala, bed nucleus of the stria terminalis; Handa & Weiser, 2014), suggesting that
estradiol could directly influence stress system function.

Estradiol impacts stress reactivity
Estradiol is associated with reactivity to laboratory stressors in the SNS and HPA axis
systems. For example, women in low estradiol menstrual cycle phases (e.g., early follicular) show
lower HPA axis reactivity compared to women in high estradiol phases (e.g., mid-luteal;
Kirschbaum et al., 1999) show lower HPA axis reactivity. Similarly, women using hormonal
contraceptives that interfere with endogenous estrogen production show lower HPA responses
compared to naturally cycling women (e.g., Nielsen, Segal, Worden, Yim, & Cahill, 2013; Roche,
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King, Cohoon, & Lovallo, 2013). Conversely, most evidence suggests that estradiol attenuates
sympathetic reactivity. For example, sympathetic reactivity increases when estradiol levels drop at
menopause (e.g., Lindheim et al., 1992), which is a change that underlies some of the well-known,
common menopausal symptoms (e.g., hot flashes), whereas estrogen treatment reduces this effect
(e.g., Komesaroff, Esler, & Sudhir, 1999). Naturally cycling women show increased sympathetic
activity during low estradiol versus high estradiol phases (e.g., McFetridge & Sherwood, 2000),
along with reduced parasympathetic activity and greater self-reported negative affect (e.g., Kanojia et
al., 2013).
Given the above evidence for the effects of estradiol on the SNS and HPA axis, estradiol
fluctuations might influence coordination of the two systems. For example, suppression of the
HPA axis is associated with heightened sympathetic reactivity (e.g., Andrews, D’Aguiar, &
Pruessner, 2012), suggesting that menstrual cycle variation in one stress system might drive or
exacerbate changes in the other. This is an important consideration, as the ratio of sympathetic to
HPA axis activity predicts stress and depression in people who have experienced adverse life
events (e.g., Ali & Pruessner, 2012). Thus, a combination of higher sympathetic and lower HPA
axis reactivity associated with low estradiol states might increase risk for post-trauma symptoms,
especially symptoms related to elevated physiological arousal.

Estradiol impacts fear and anxiety responses
In addition to elevated neural and neuroendocrine reactivity to stressors, lower estradiol
has also been linked with behavioral indices of maladaptive fear and anxiety in the absence of
actual threat. For example, in both women and female rodents, estrogens facilitate fear extinction, a
learning process in which an organism is presented with a previously aversively conditioned cue in
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the absence of any aversive event (e.g., Graham & Milad, 2013). Successful extinction learning is
indexed by diminished conditioned fear responses (e.g., skin conductance response), whereas
extinction impairments are indexed by persistent fear responses to stimuli that no longer signal threat
(Maren, 2001, for review).
During trauma exposure, people can acquire associations between the traumatic event and
innocuous stimuli in the environment. Post-trauma, persistent responses to these cues can lead to
distressing PTSD symptoms, and a robust literature supports impaired fear extinction as a candidate
mechanism underlying vulnerability for anxiety and stress-related disorders (e.g., Hermann, Ziegler,
Birbaumer, & Flor, 2002; Michael, Blechert, Vriends, Margraf, & Wilhelm, 2007), including PTSD
(e.g., Blechert, Michael, Vriends, Margraf, & Wilhelm, 2007; Milad et al., 2008; Norrholm et al.,
2011). Additionally, given that extinction learning is the basis of exposure therapy, extinction deficits
can confer resistance to treatment (e.g., Rothbaum et al., 2014; Sijbrandij). Thus, extinction deficits
associated with hormone events could increase symptom severity and hinder treatment in traumaexposed women.
Converging evidence from studies with women and animal models suggests that low
estradiol states are associated with impaired extinction. In both women and female rodents, estrogenblocking hormonal contraceptives hinder fear extinction, whereas estrogen treatment reverses this
effect (e.g., Graham & Milad, 2013; Lonsdorf et al., 2015). In rodents, natural estrous cycle variation
in estrogen has also been associated with extinction learning, with the most successful extinction
observed during the proestrus (higher estrogen phase of the estrous cycle; e.g., Milad, Igoe, LebronMilad, & Novales, 2009). In women, individual variation in estradiol is also associated with
extinction learning, such that lower levels are associated with greater fear following extinction (e.g.,
Hwang et al., 2015; Milad et al., 2010; Milligan-Saville & Graham, 2016; White & Graham, 2016;
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Zeidan et al., 2013) and women in the late follicular phase (high estradiol) show better extinction
learning relative to those in early follicular phase (e.g., Antov & Stockhorst, 2014). Further, women
taking hormonal contraceptives, which generally reduce levels of endogenous estradiol, show
impaired extinction learning compared to naturally cycling women (e.g., Lonsdorf et al., 2015; Merz
et al., 2012). Associations between extinction and estradiol or menstrual cycle phase have been
observed in healthy women (e.g., Milad et al., 2010) and women with PTSD (e.g., Glover et al.,
2012) and other affective disorders (e.g., specific phobia; Li & Graham, 2016). Some evidence,
however, suggests that the direction of these associations might differ between healthy women and
women with PTSD. For example, in one study, healthy trauma-exposed women showed better
extinction learning during the mid-luteal phase, in which progesterone levels peak, compared to the
early follicular phase, whereas this relationship is opposite in women with PTSD (Pineles et al.,
2016).
In addition to fear extinction, lower estradiol has also been associated with other models of
maladaptive fear and anxiety. For example, in rodents, behavioral indices of anxiety on standard
laboratory paradigms (e.g., the elevated plus maze) are greater during the diestrum (lower estrogen)
versus proestrus (higher estrogen) phase of the estrous cycle (e.g., Mora, Dussaubat, & Díaz-Véliz,
1996). In women, lower estradiol has been linked with impaired inhibition of fear in the presence
of safety cues (e.g., Glover et al., 2013).
There is also some evidence that lower estradiol is associated with intrusive memories
following exposure to highly arousing unpleasant information in the context of laboratory
stressors, although the results are somewhat mixed. Women in the luteal versus follicular phase
reported greater intrusive memories following exposure to an aversive film clip (Ferree, Kamat,
& Cahill, 2011). However, this result is difficult to interpret with regard to the role of estradiol,
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given considerable fluctuations in both estradiol and progesterone that occur across the luteal and
follicular phases. Additionally, some evidence suggests interactive effects of estradiol and
progesterone on intrusive memories. For example, women in the early luteal phase (low estradiol
and increasing progesterone) reported greater intrusive memories compared to women in the late
luteal (low estradiol and progesterone) or mid-follicular phases (increasing estradiol and low
progesterone) (e.g., Soni, Curran, & Kamboj, 2013). Increased intrusive memories during the
early luteal phase were driven by the interaction of estradiol and progesterone, with no effect of
estradiol alone.
In contrast, results from studies that control for the effects of progesterone, and thereby
focus on the effects of estradiol alone, suggest that estradiol protects against intrusive memories.
For example, lower estradiol has been linked with self-reported intrusive memories, with no
association between progesterone and intrusive memories (e.g., Wegerer, Kerschbaum, Blechert,
& Wilhelm, 2014). Further, during processing of aversive laboratory stimuli, estradiol has also
been associated with neural activity in affective brain areas. In naturally cycling women, higher
estradiol has been associated with increased activity in the ventromedial prefrontal cortex, which
has been implicated in the downregulation of negative affect in response to unpleasant stimuli
(Miedl, Wegerer, Kerschbaum, Blechert, & Wilhelm, 2018). Conversely, women in lower
estradiol states, such as women in the late luteal versus late follicular phase (Ossewaarde et al.,
2010), and women using hormonal contraceptives (Miedl et al., 2018), show increased activity in
limbic (i.e., amygdala, insula) and cingulate areas (e.g., dorsal anterior cingulate cortex), which
are thought to amplify fear and stress-related responses (e.g., Milad et al., 2007).
Finally, under conditions of elevated SNS activity upon exposure to affective
information, lower estradiol has been linked with biased memory for negatively valenced
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compared to positively valenced affective information (Nielsen, Barber, Chai, Clewett, & Mather,
2015). Given that people experience high SNS activity when confronted with a traumatic event,
estradiol could affect the consolidation of traumatic memories and therefore influence later
symptoms. Together, these results suggest that low estradiol states are associated with increased
vulnerability to negative affect and intrusive memories following exposure to distressing content.
In sum, associations between lower estradiol and affective responses including fear and
anxiety have been observed in healthy women and women with PTSD, suggesting typical
increases in risk for persistent or exaggerated fear responses during low estradiol phases of the
cycle. In trauma-exposed women, low estradiol phases might additionally be associated with risk
for PTSD symptoms. For example, failure to inhibit responses to cues associated with a
traumatic event and vulnerability to intrusive memories following exposure to distressing content
are two mechanisms that could directly relate to PTSD re-experiencing symptoms.
Consistent with the notion that estradiol protects against PTSD symptoms, women who
were administered emergency contraception (EC) shortly following sexual trauma reported
reduced symptom severity (Ferree, Wheeler, & Cahill, 2012). Unlike standard hormonal
contraceptives, which deliver low doses of synthetic hormones over a period of time and reduce
endogenous ovarian hormone production, EC delivers a large single dose of synthetic hormones.
Among women admitted to the emergency room within hours following sexual trauma, women
who received synthetic estrogen- and progestin-based EC had lower PTSD symptom severity at
6-month follow-up relative to women who received progestin only EC, or women who declined
EC (Ferree et al., 2012).
Initial prospective evidence also suggests that endogenous estradiol is protective against
PTSD symptoms. Among women in the emergency room, lower estradiol, measured within a
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few hours post-trauma, was associated with greater PTSD symptom severity at 1 and 3-month
follow-ups (Jovanovic, 2017). In addition to individual differences in risk for symptoms
associated with estradiol, natural fluctuations in estradiol across the menstrual cycle might also
predict patterns of vulnerability for symptoms.

Menstrual cycle variation and psychological symptoms
Some work has documented normative menstrual cycle variation in a variety of
psychological symptoms. Most evidence suggests that estradiol protects against negative affect (e.g.,
anxiety, depressed mood, neuroticism). For example, greater self-reported psychological symptoms
have been observed in women during the late luteal phase, when estradiol levels are declining to
baseline, relative to the mid to late follicular phases, when estradiol levels are rising (e.g., Gonda et
al., 2008; Kanojia et al., 2013). Reduced self-reported psychological symptoms have also been
observed during the mid-luteal phase, which is characterized by relatively high estradiol, but also
high progesterone (e.g., Walder, Statucka, Daly, Axen, & Haber, 2012).
In addition to psychological symptoms, menstrual cycle phase has been associated with
lifestyle and health behaviors that could influence mental health. For example, women show
increased binge eating during the mid and late luteal phase, when ovarian hormones decline, versus
the late follicular phase, when estradiol increases (Klump, Keel, Culbert, & Edler, 2008). Female
smokers show increased cigarette consumption, along with greater self-reported depressed mood
during the early follicular and luteal phases compared to the late follicular phase (e.g., Sakai &
Ohasi, 2013). Further, among female smokers attempting to quit, greater withdrawal symptoms have
been observed during the mid to late luteal phase versus mid to late follicular phase (e.g., Allen,
Allen, Lunos, & Hatsukami, 2009).
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In normative populations, lower estradiol phases have been linked with increased risk for
clinical symptoms, particularly in women with trait vulnerabilities. For example, among women
with higher anxiety sensitivity, greater cognitive panic symptoms related to physical changes
(i.e., CO2 challenge) were reported by women in the late luteal (lower estradiol) compared with
the late follicular (higher estradiol) phase (Nillni, Rohan, & Zvolensky, 2012). Similarly, in
women with borderline personality features, symptoms of borderline personality disorder varied
across the menstrual cycle, such that lower estradiol predicted increased symptoms, but only
when progesterone levels were high (Eisenlohr-Moul, DeWall, Girdler, & Segerstrom, 2015).
Menstrual cycle variation in symptoms has also been observed in a variety of clinical
conditions. For example, women with premenstrual dysphoric disorder (PMDD) demonstrate a
well-defined pattern of fluctuations in symptoms across the menstrual cycle. PMDD is
characterized by a constellation of severe cognitive, affective and physical symptoms that are
confined to the late luteal phase and the early follicular phase during menses (APA, 2013), which
represent a low estradiol portion of the menstrual cycle. For a diagnosis of PMDD, these
symptoms must remit during the mid follicular phase when estradiol levels increase.
In addition to fluctuations in self-reported symptoms, women with PMDD show
measurable increases in physiological reactivity (e.g., exaggerated startle; Epperson et al., 2007),
increased panic responses to biological challenges (e.g., C02 challenge; Nillni, Pineles, Rohan,
Zvolensky, & Rasmusson, 2017) and impaired performance on cognitive tasks (e.g., Reed, Levin,
& Evans, 2008) during menses or the late luteal (lower estradiol) phases relative to the mid or
late follicular (higher estradiol) phases. Consistent with negative affect and elevated arousal,
women with PMDD show greater limbic and reduced prefrontal regulatory activity during
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affective processing relative to healthy controls, but only during the late luteal phase
(Protopopescu et al., 2008).
Menstrual cycle phase variation has also been reported in other clinical conditions, such
as eating disorders. For example, women with bulimia show increased binge eating during lower
estradiol phases of the cycle (e.g., Edler, Lipson, & Keel, 2007), although some of these effects
are potentially mediated by progesterone. The early follicular period (low estradiol) is also
associated with the greatest risk for suicide attempts (e.g., Sein, Chodorowski, Ciechanowicz,
Wiśniewski, & Pankiewicz, 2005).
Some initial evidence suggests that trauma-exposed women experience greater general
psychological distress during low estradiol menstrual cycle phases (e.g., Nillni et al., 2015), but
less is known about how cyclic variation in estradiol contributes to trauma-related symptoms.
Additionally, some of the evidence for differences in negative affect or stress-related symptoms
by menstrual cycle phase is based on comparisons between women in the entire follicular and
luteal phases, despite the variability in ovarian hormones within these broad phases. Other
evidence is based on comparisons between women in the early follicular and mid-luteal phases.
However, given that the luteal phase is characterized by increases in both estradiol and
progesterone, it is difficult to disentangle the unique contributions of the two hormones. For
example, greater intrusive memories in trauma survivors have been reported during the midluteal (higher estradiol) phase of the cycle (e.g., Bryant et al., 2011), but this result could also
reflect high progesterone, rather than estradiol. Finally, many previous studies have relied on
data gathered from single laboratory sessions or a small number of sessions. These studies
cannot capture patterns of daily affective experiences over the course of the menstrual cycle.
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To acquire a more nuanced understanding of how daily affect is influenced by
fluctuations in estradiol, it is important to track affective experiences at different points in the
menstrual cycle. In particular, it is important to assess participant affect and symptoms during
high and low menstrual cycles phases, while controlling for progesterone levels. The transition
from the early to late follicular phase captures a portion of the cycle marked by estradiol change,
as levels increase from the cycle baseline and approach the pre-ovulation peak. Additionally, by
using an experience sampling method, rather than relying on single lab visits during each phase,
researchers can more accurately capture daily affective experiences across low and high estradiol
phases.

Ecological momentary assessment for capturing daily affect
Traditional assessments of affect and clinical symptoms generally take place in a
laboratory setting and require participants to report on symptoms over a defined period of time.
For example, some PTSD assessments ask participants to report on symptoms experienced over
the past month (First, Spitzer, Gibbon & Williams, 1996; Weathers, Blake, Schnurr, Kaloupek,
Marx & Keane, 2013a). These retrospective assessments are limited by biases in reporting, as
self-report can be influenced by momentary affect (Mill, Realo, & Allik, 2016). Ecological
Momentary Assessment (EMA) offers an alternative to single timepoint assessments and allows
researchers to track phenomena of interest over a period of time (e.g., Moskowitz & Young,
2006; Ebner-Priemer & Trull, 2009). EMA methods entail prompting participants to respond to
questionnaires assessing momentary affect, cognitions or behaviors using handheld devices.
These methods enable more accurate reporting of affect and symptoms over time, and also
capture experiences within naturalistic settings (i.e., participants’ daily life settings).
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Given previous evidence linking estradiol with affect, menstrual cycle phase could
influence trauma symptoms, as well as daily affective experiences more broadly. Affect refers to
a person’s subjective experience at a given moment and varies along two well-established
dimensions of valence (unpleasant to pleasant) and arousal (low to high activation) (e.g., Barrett,
2006; Posner, Russell, & Peterson, 2005; see Figure 3). Estradiol could influence patterns of
daily affect along either or both dimensions. For example, given the evidence for greater fear and
anxiety responses associated with lower estradiol, menstrual cycle phases characterized by low
estradiol (e.g., early follicular phase) might be associated with more frequent aversive daily
affective experiences. In particular, lower estradiol might increase risk for negatively valenced
high arousal states, including PTSD symptoms.

High Arousal

Unpleasant

Pleasant

Figure 3. Circumplex model of affect which
includes the dimensions of valence and
arousal. Aversive affective experiences,
defined as negatively valenced (unpleasant)
high arousal states, are located within the
upper left quadrant.

Low Arousal

Aims and hypotheses
The first aim of this study was to test the relation between estradiol and stress reactivity
to a naturalistic trauma reminder. The second aim was to test the relation between estradiol and
daily affective experiences, including PTSD symptoms. To address our specific aims, we used a
multi-method approach that included both cross-sectional and experience sampling methods. We
measured physiological stress reactivity to a naturalistic trauma reminder and assessed trauma-
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related symptoms during a structured clinical interview and over the course of a 10-day
ecological momentary assessment phase that included low and high estradiol menstrual phases.
We hypothesized that in trauma-exposed women, lower estradiol would be associated with greater
severity of trauma-related symptoms (Hypothesis 1) and a stress response profile of greater
sympathetic and lower HPA axis reactivity to a trauma reminder (Hypothesis 2). We also
hypothesized that women would report more frequent aversive affective experiences (i.e., unpleasant
high arousal states), including PTSD symptoms, during a low versus high estradiol phase of the
menstrual cycle (Hypothesis 3). These hypotheses were generated in accordance with previous
studies that observed increased psychological symptoms during low estradiol phases of the menstrual
cycle and with the literature on estradiol and its relation to stress system function.
Finally, as exploratory analyses, we examined associations between estradiol and affective
variability across the early and late follicular phases. These analyses allowed us to test the potential
effect of within-person variability in estradiol on affect and PTSD symptoms.

2. Method
2.1. Participants
We recruited 40 naturally cycling premenopausal trauma-exposed women who were
undergraduate students fulfilling credit requirements for introductory psychology at an urban
university in the northeastern US. Prior to the study, we conducted a power analysis and
determined that a sample of approximately 30 participants would provide adequate power to
detect differences in affect and symptoms by menstrual cycle phase. Given subject attrition
during the EMA portion of the study, we recruited 10 additional women.
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We recruited participants according to self-reported exposure to potentially traumatic
events on a standard laboratory prescreen, and trauma exposure was subsequently confirmed
during the clinical interview.
During both recruitment and a clinical interview, we verified that participants did not
meet any exclusion criteria for the study, which included: (1) current use of hormonal
contraceptives or use of hormonal contraceptives in the past 6 months, (2) pregnancy or lactation
within the past year (3) use of psychotropic or steroid medications known to influence
physiological arousal or stress system function (e.g., betablockers, anxiolytic drugs,
corticosteroids), (4) habitual cigarette smoking, which is known to influence salivary flow rate
and salivary stress biomarkers (e.g., Granger et al., 2007), (5) meeting criteria for current Axis I
disorders other than PTSD and (6) younger or older than the 18-35 age range.
2.2. Recruitment
Recruitment consisted of two steps. First, we selected potential participants for invitation
to the study according to self-reported potential trauma exposure on an introductory psychology
prescreen, and then participants completed a phone screen assessing menstrual cycle-related
inclusion criteria. We recruited participants from the subject pool according to responses on the
Life Events Checklist (LEC; Weathers et al., 2013a), which is a 17-item self-report screen for
exposure to potentially traumatic life events (see Appendix). The respondents checked either
“Happened to me”, “Witnessed it”, “Learned about it”, “Not sure” or “Doesn’t apply to me” for
each event. We recruited people who responded with “Happened to me” for one or more
traumatic event items on the LEC.
Potential participants received an email invitation to the study with instructions to contact
the laboratory for a phone screen. We used the phone screen to assess menstrual cycle regularity

21
and use of medication and other substances that would render participants ineligible to
participate. Participants were asked to report on the date of their most recent menstrual cycles
and approximate average cycle length. Inclusion criteria for the study included menstrual cycle
regularity, defined as an average cycle length between 25 and 36 days and no missed periods
within the past six months. We also asked participants about use of hormonal contraception and
cigarette smoking. We only recruited participants who were non-smokers and who were not
currently using hormonal contraceptives and had not used hormonal contraceptives within the
past 6 months.
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2.3. Procedure
The study included two parts: a laboratory visit and a 10-day ecological momentary
assessment (EMA) period spanning the early and late follicular menstrual cycle phases. All study
procedures were approved by Institutional Review Board and were conducted in accordance with
The Code of Ethics of the World Medical Association (Declaration of Helsinki).
2.3.1. Laboratory visit
The laboratory visit consisted of informed consent, a clinical interview, and training in
the use of a handheld device for the EMA portion of the study. During the laboratory visit,
participants provided saliva samples in the post-consent resting period, which served as a study
baseline, and following a discussion of a traumatic event.
Clinical interview. All participants completed a structured clinical interview to verify the
presence of trauma exposure and to assess symptoms of PTSD and other Axis I disorders. The
interview included the Structured Clinical Interview for DSM-IV Disorders (SCID; First,
Spitzer, Gibbon & Williams, 1996) and the Clinician-Administered PTSD Scale (CAPS;
Weathers et al., 2013).
The SCID is a structured diagnostic assessment for DSM-IV Axis I disorders (e.g., mood,
anxiety, substance use and eating disorders, psychotic symptoms). We conducted all modules of
the SCID to exclude participants who met criteria for current disorders with the exception of
PTSD. We verified trauma exposure using Criterion A of the PTSD module: (1) the person
experienced, witnessed or was confronted with an event or events that involved actual or
threatened death or serious injury, or a threat to the physical integrity of the self or others; and
(2) the person’s response involved intense fear, helplessness or horror. Participants briefly
described the traumatic event, and this discussion also served as a trauma reminder.
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After the participant described the traumatic event, we assessed PTSD symptoms over the
past month using the Clinician-Administered PTSD Scale (CAPS). Unlike other PTSD measures,
such as the SCID, which yield only binary symptom reports (by asking participants whether they
experienced a given symptom over the past month), the CAPS assess both symptom count and
severity. The severity score is based on both the frequency and intensity of reported symptoms.
In addition to psychiatric symptoms, we also assessed general health, medication and
substance use and recent menstrual cycle history during the interview session. Participants
provided the dates of their previous two menstrual cycles and approximate average cycle length.
The EMA portion of the study started on day 2 (early follicular phase) of the next menstrual
cycle. We calculated mean cycle length using the dates of previous menstrual cycles and the date
of the cycle that started during the EMA portion of the study.
Saliva collection. Participants provided saliva samples following informed consent,
which served as a study baseline, immediately following trauma description during the interview
and 20 minutes later (see Figure 4). At each timepoint, participants provided samples using the
passive drool method via Salimetrics saliva collection aids (Salimetrics, LLC). We instructed
participants to allow saliva to pool naturally in the mouth and to release the saliva through the
saliva collection aid into a cryovial. The passive drool method was preferred over a salivettebased method, as the latter has been shown to distort gonadal hormone readings (Shirtcliff,
Granger, Schwartz, & Curran, 2001). All participants had been awake for a minimum of one hour
prior to the study session, ensuring that our timepoints did not overlap with the cortisol
awakening response. Participants had refrained from eating or drinking, except for water, for one
hour prior to the study session.
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The first saliva sample (T1) was collected in the resting period following informed
consent at approximately 10:05 AM. We collected the first sample at the same time for all
participants to control for diurnal variation in levels of cortisol, alpha amylase and estradiol (e.g.,
Bao et al., 2003; Nater, Rohleder, Schlotz,, Ehlert, & Kirschbaum, 2007). This post-consent
sample served as a study baseline. Although not a true baseline in the sense that participants’
stress systems might have been elevated relative to a typical day (resting at home versus in the
laboratory), the study baseline served as a point of comparison to the post-stressor samples.
The second sample (T2) was collected immediately following description of the
traumatic event during the interview. The second sample allowed us to capture peak AA, as this
enzyme increases almost immediately (within 2-5 minutes) post-stressor onset (Nater et al.,
2005; Rohleder, Nater, Wolf, Ehlert, & Kirschbaum, 2004). The third sample (T3) was collected
exactly 20 minutes after the second.
Levels of salivary alpha amylase at each timepoint indexed sympathetic activity at that
timepoint. Given that cortisol peaks approximately 20 minutes following a stressor (Kirschbaum
& Hellhammer, 2000), cortisol levels at each timepoint indexed HPA axis activity approximately
20 minutes prior to collection. The samples were aliquoted into cryovials for later assays and
stored in a -20 C freezer until the time of analysis.

Figure 4. Saliva collection during the laboratory visit. Participants provided saliva samples at
baseline, during and after discussion of a traumatic event.
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2.3.2. Ecological momentary assessment phase
Ecological momentary assessment procedure. The ecological momentary (EMA) phase
comprised a period of ten days spanning the early follicular (low estradiol) and late follicular
(higher estradiol) phases. During the ten days, participants completed questionnaires at five daily
timepoints, for a total of fifty assessment timepoints. The timing and length of our EMA design
allowed us to capture the scope of daily affective experiences across low and high estradiol
portions of the cycle, while also being within the window after which EMA compliance has been
shown to decrease (Broderick, Schwartz, Shiffman, Hufford, & Stone, 2003).
We provided each participant with a handheld device (i.e., android phone) for the
duration of the ten-day EMA phase. During the EMA phase, participants completed
questionnaires at five daily assessment points: after waking, before bed and at three variable
daytime assessment points. The three daytime assessment points were programmed to occur
semi-randomly at approximately three-hour intervals within the participant’s typical waking
hours. At each daytime assessment point, participants received a text message instructing them to
complete a questionnaire. Participants were asked to complete daytime assessments within 30
minutes of receiving a prompt to the extent that this was possible.
The EMA phase began on day 2 following the onset of menstruation and went through
day 11 of the cycle. The early follicular phase, which is characterized by low estradiol and
progesterone, was operationalized as menstrual cycle days 2-6. The late follicular phase, which is
characterized by higher estradiol and low progesterone, was operationalized as days 7-11. On the
first day of her menstrual cycle, each participant contacted an experimenter to report that her
cycle had started, and the EMA prompts were programmed to start the following day. All
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completed assessments were automatically time-stamped, and EMA data were uploaded
automatically to the laboratory server.
We confirmed that participants were in the expected menstrual cycle phases during the
EMA portion of the study by measuring levels of gonadal hormones in two at-home saliva
samples. Participants collected at-home saliva samples on the first and last days of the EMA
phase, which correspond to Day 2 (early follicular phase) and Day 11 (late follicular phase of the
cycle). We instructed participants to collect the saliva samples via the passive drool method
immediately upon waking, prior to moving around, brushing their teeth, or consuming food or
beverages (other than water). Participants were accustomed to the passive drool method and were
able to practice under the guidance of an experimenter during the laboratory visit. At-home
saliva samples were stored in participants’ home freezers. After the EMA portion of the study,
participants transported the samples to the lab in insulated lunch bags. To reduce overall transit
time for the samples, participants were asked to schedule transport on days when they could
travel directly to lab from home. Once they arrived at the lab, the samples were stored in a -20 C
freezer and prevented from undergoing any additional freeze-thaw cycles prior to estradiol assay.
Ecological momentary assessment measures. An overview of the daily questionnaire
items is presented in Table 1. The EMA questionnaires included measures for affect and traumarelated symptoms and also assessed lifestyle behaviors.
At all assessment points, participants rated current affect (i.e., valence, unpleasant to
pleasant; arousal, low to high). Valence was rated on a scale ranging from 1-9, where “1” was
“extremely unpleasant”, “5” was “neutral” and “9” was “extremely pleasant”. Arousal was also
rated on a scale ranging from 1-9, where “1” was “extremely non-stimulated or activated”, “5”
was “moderately stimulated or activated” and “9” was “extremely stimulated or activated”. We
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operationalized unpleasant high arousal states as assessment points where participants rated
valence below “5” and arousal above “5”.
The morning and evening questionnaires also included the Positive and Negative Affect
Schedule (PANAS-SF; Watson, Clark, & Tellegen, 1988). The PANAS-SF is a 10-item selfreport measure of current positive and negative affective states (e.g., upset, inspired). For each
item, the participant indicated the extent to which she was currently feeling that affective state on
a scale ranging from “1” (very slightly or not at all) to “5” (extremely).
We assessed trauma-related symptoms once each day on the evening questionnaires using
the PTSD Checklist for DSM-5 (PCL-5; Weathers et al., 2013c). The PCL-5 is a 20-item
measure that assesses DSM-5 symptoms of PTSD. For each symptom, the participant reported
the extent to which she was bothered by the symptom that day on a scale ranging from 0 (“not at
all”) to 4 (“extremely”).
The daily morning and evening questionnaires also included lifestyle items. On the
morning questionnaires, participants reported on their sleep quality the night before, specifically,
the number of hours that they slept and any nightmares or interruptions to their sleep. On the
evening questionnaires, participants reported daily consumption of alcohol and other substances
and exercise.

Table 1. Content of morning, daytime and evening EMA assessments
Morning
Daytime (3x/Day)
Evening
Current Affect
Current Affect
Current Affect
Arousal (1-9)
Arousal (1-9)
Arousal (1-9)
Valence (1-9)
Valence (1-9)
Valence (1-9)
PANAS (10-item)
PANAS (10-item)
Sleep Quality
Sample prompt
Daily Stress Symptoms (0-4)
Number hours? schedules:
Irritability, Flashback,
Nightmares?
11 am, 2:30 pm, 5 pm
Jumpiness, Intrusive thoughts,
Interrupted?
11:30 am, 4 pm, 7 pm
Physiological arousal, Distress about
12:30 pm, 5 pm, 8 pm
thoughts, Reminders of stressor,
Difficulty calming self, Hyper-alertness,
*Variable times;
Avoidance of activities Feeling numb,
counterbalanced by
Blunted feelings, Risky behavior,
day & participant
Trouble sleeping, Negative cognitions,
Difficulty concentrating
Exercise (amount, type)
Caffeine (amount, type, time)
Alcohol (amount, time)
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2.2.3. Salivary biomarker assays
Salivary biomarker assays were conducted in-house by lab personnel and all samples were
processed in duplicate. We assayed the three samples collected during the laboratory visit for levels
of the stress biomarker cortisol and the surrogate stress biomarker alpha amylase.
We conducted alpha amylase assays using Salimetrics kinetic reaction assay kits (Salimetrics,
LLC), which utilize a chromogenic substrate, 2-chloro-p-nitrophenol, linked to maltotriose. The
amount of alpha amylase present in each sample is directly proportional to the increase in
absorbance, measured spectrophotometrically by a standard plate reader at 405 nm. The intraand inter-assay coefficients of variation for these kits are less than 7.5% and 6%, respectively.
We conducted cortisol assays using Salimetrics enzyme immunoassay kits (Salimetrics,
LLC), which use a microtiter plate coated with monoclonal anti-cortisol antibodies. Cortisol in
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samples and standards competes with cortisol conjugated with peroxidase for the antibody
binding sites. The amount of cortisol enzyme conjugate detected is inversely proportional to the
amount of cortisol present in the sample, measured spectrophotometrically by a standard plate
reader at 450 nm. The intra- and inter-assay coefficients of variation for these kits are less than
7% and 10%, respectively.
We measured levels of estradiol present on the morning of the laboratory visit (T1). To
confirm appropriate cycle phase during the EMA phase, we also measured levels of estradiol and
progesterone in the at-home saliva samples. We conducted estradiol assays using Salimetrics
enzyme immunoassay kits (Salimetrics, LLC). The kit utilizes a microtiter plate coated with
rabbit anti-estradiol antibodies. Estradiol in samples and standards competes with estradiol
linked to horseradish peroxidase for the antibody binding sites. The amount of estradiol linked to
horseradish peroxidase detected is inversely proportional to the amount of estradiol present in the
sample, measured spectrophotometrically by a standard plate reader at 450 nm. The intra- and
inter-assay coefficients of variation for these kits are less than 8.5 and 9%, respectively.
We measured levels of progesterone in at-home saliva samples to ensure that participants
remained in the follicular phase for the duration of the EMA protocol. We conducted
progesterone assays using Salimetrics enzyme immunoassay kits (Salimetrics, LLC), which
utilize a microtiter plate coated with rabbit anti-progesterone antibodies. Progesterone in samples
and standards competes with progesterone conjugated to horseradish peroxidase for the antibody
binding sites. The amount of progesterone conjugate detected is inversely proportional to the
amount of progesterone present in the sample, measured spectrophotometrically by a standard
plate reader at 450 nm. The intra- and inter-assay coefficients of variation for these kits are less
than 8.5% and 10%, respectively.
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2.4. Data analyses
2.4.1. Estradiol and PTSD symptoms
We used Pearson product-moment correlations to test the hypothesized associations
between estradiol and PTSD symptom count and severity as reported during the clinical
interview.

2.4.2. Estradiol and stress reactivity
We used Pearson product-moment correlations to test the hypothesized associations
between estradiol and sympathetic and HPA axis reactivity to the trauma reminder. Sympathetic
nervous system activity at each timepoint was indexed by salivary alpha amylase (AA) at that
timepoint and the difference between levels of AA at the first and second timepoints (T2-T1)
indexed sympathetic reactivity. Conversely, given that salivary cortisol levels at each timepoint
index HPA axis activity approximately 20 minutes prior to collection, we calculated HPA axis
reactivity as the difference in cortisol between the second and third timepoints (T3-T2).

2.4.3. Menstrual cycle phase and stress reactivity
In addition to testing associations between estradiol level and stress reactivity, we also
tested the association between menstrual cycle phase on the day of the laboratory visit and stress
reactivity. We determined participants’ menstrual cycle phase during the laboratory visit using
the dates of their three most recent menstrual cycles and average cycle length. We categorized
participants into two groups: low and high estradiol phase. The low estradiol phase group
comprised participants in the early follicular, early luteal and late luteal phases, whereas the high
estradiol phase group comprised participants in the late follicular/peri-ovulatory and mid-luteal
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phases. We used Wilcoxon rank-sum tests to test group differences in alpha amylase and cortisol
reactivity.

2.4.4. Menstrual cycle phase and daily affect
Ecological Momentary Assessment data was analyzed by collapsing across the early
follicular (days 2 to 6) and late follicular (days 7 to 11) phases. To test differences in daily
affective experiences by menstrual cycle phase, we used paired samples t-tests to test differences
in self-reported valence, arousal and PTSD symptoms during the early and late follicular phases.
Additionally, to test the relation between changes in estradiol and daily affect, we calculated
estradiol increase for each participant as the difference between estradiol detected in the late
follicular and early follicular at-home saliva samples. We used Pearson product-moment
correlations to test the association between estradiol increase and daily affect measures (i.e.,
valence, arousal and PTSD symptoms).

3. Results
3.1. Descriptive data
We recruited 40 naturally cycling premenopausal trauma-exposed women (M age = 21.9,
SD = 4.2, range: 18-33). Participant characteristics are reported in Table 2. Consistent with the
local metropolitan area, our population was diverse. Participants had regular menstrual cycles
with average cycle length varying between 26 and 35 days (M = 30.5, SD = 3.4).
All participants reported experiencing at least one traumatic event. Trauma type varied,
although for the majority of our sample, the index trauma (i.e., traumatic event that affected them
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the most) was of an interpersonal nature, and the most frequently reported index trauma was
sexual assault (see Table 2).
Hormone levels over the course of the study are shown in Table 3. Four participants had
estradiol or progesterone values in the at-home samples that were inconsistent with the expected
menstrual cycle phase and were therefore excluded from all analyses with EMA data.
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Table 2. Participants
Variable

Statistic

Age in years, M (SD), range
Race/ethnicity, n (%)
Asian/Pacific Islander

8 (20.0)

Black, non-Hispanic

6 (15.0)

Hispanic

10 (25.0)

White, non-Hispanic

11 (27.5)

Multiple

3

(7.5)

Other race

2

(5.0)

Average cycle length (days), M (SD), range

30.5 (3.4), 26-35

Trauma type, n (%)
Interpersonal
Non-interpersonal

33 (82.5)
7 (17.5)

Index trauma, n (%)
Sexual assault

20 (50.0)

Physical assault

7 (17.5)

Transportation accident

6 (15.0)

Other unwanted sexual experience

2 (5.0)

Assault with a weapon

2 (5.0)

Chronic bullying

1 (2.5)

Warzone

1 (2.5)

Fire

1 (2.5)
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Table 3. Stress and gonadal hormone levels over the course of the study
Analyte

M (SD)

Laboratory visit
Morning estradiol (pg/ml)

1.21 (0.49)

Low estradiol phase group estradiol (n = 23)

1.09 (0.43)

Early follicular phase estradiol ( n = 13)

1.09 (0.55)

Early luteal phase estradiol (n = 3)

1.29 (0.18)

Late luteal phase estradiol (n = 7)

1.01 (0.23)

High estradiol phase group estradiol (n = 17)

1.36 (0.54)

Late follicular phase estradiol (n = 10)

1.38 (0.58)

Mid-luteal phase estradiol (n = 7)

1.33 (0.52)

Baseline alpha amylase (U/ml)

43.80 (35.19)

Post-stressor alpha amylase (U/ml)

56.62 (45.13)

Baseline cortisol (µg/dl)

0.17 (0.09)

Post-stressor cortisol (µg/dl)

0.15 (0.07)

EMA phase
Early follicular phase estradiol (pg/ml)

0.96 (0.30)

Late follicular phase estradiol (pg/ml)

1.66 (1.10)

Late follicular phase progesterone (pg/ml)

70.0 (30.8)

Note: The range of expected progesterone is 28-82 pg/ml for the follicular phase
and 127-446 pg/ml for the luteal phase (Soni et al., 2013). Our observed ~70% increase in
estradiol from the early follicular to late follicular phase is consistent with other studies with
healthy naturally-cycling women (e.g., Colzato et al., 2010).

3.1. Trauma-related symptoms
Trauma symptoms reported during the clinical interview are summarized in Table 4.
Eight participants met criteria for a provisional PTSD diagnosis. However, consistent with our
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high-functioning undergraduate sample, participants scored at the lower end of the symptom
severity range.
Table 4. Trauma symptoms
Variable (possible range)

M (SD)

Re-experiencing symptom severity (0-20)

2.4 (2.5)

Re-experiencing symptom number (0-5)

0.7 (1.1)

Avoidance symptom severity

1.8 (1.8)

Avoidance symptom number (0-5)

0.7 (0.8)

Neg cognitions & affect symptom severity (0-28)

4.4 (4.2)

Neg cognitions & affect symptom number (0-7)

1.5 (1.8)

Arousal symptom severity (0-24)

3.0 (3.1)

Arousal symptom number (0-6)

1.0 (1.2)

Total symptom severity (0-80)

11.6 (9.9), range 0-32

Total symptom number (0-20)

3.9 (4.1), range: 0-12

Provisional current PTSD diagnosis, n (%)

8 (20%)

3.2. Estradiol and PTSD symptoms
Because estradiol levels were not normally distributed, the values were square root
transformed. Associations between estradiol on the morning of the laboratory visit and PTSD
symptom are shown in Table 5. Lower estradiol was associated with greater total number, r= 0.35, p = 0.025, and severity of trauma-related symptoms, r = -0.32, p = 0.041, as reported
during the clinical interview. In addition to overall symptom count and severity, we also tested
correlations between estradiol and PTSD symptom clusters. Lower estradiol was associated with
greater re-experiencing (B cluster) symptom number: r = -0.34, p = 0.034, but not re-

36
experiencing symptom severity, r= -0.20, p = 0.222. Lower estradiol was also associated with
greater avoidance symptom (C cluster) number, r = -0.36, p = 0.022 and severity, r = -0.36, p =
0.024, as well as greater arousal (E cluster) symptom number, r = -0.35, p = 0.025 and severity, r
= -0.35, p = 0.028. Estradiol was not associated with negative alterations in cognitions and mood
(D cluster) symptom number, r = -0.21, p = 0.195, or severity, r = -0.24, p = 0.133 (see Figure
5).

Table 5. Correlations between estradiol on the morning of the laboratory
visit and PTSD symptoms
Morning estradiol
Total PTSD symptom number

r = -0.35*

Total PTSD symptom severity

r = -0.32*

Re-experiencing symptom number

r = -0.34*

Re-experiencing symptom severity

r = -0.20

Avoidance symptom number

r = -0.36*

Avoidance symptom severity

r = -0.36*

Neg cognitions & affect symptom number

r = -0.21

Neg cognitions & affect symptom severity

r = -0.24

Arousal symptom number

r = -0.35*

Arousal symptom severity

r = -0.35*

Note: * p < 0.05
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Figure 5. Relation between estradiol and PTSD symptoms. Lower estradiol on the morning of
the lab visit was associated with greater total PTSD symptom count and severity, greater reexperiencing (B cluster) symptom count, avoidance (C cluster) symptom count and severity, and
arousal (E cluster) symptom count and severity. Estradiol was not associated with negative
alterations in cognitions and mood (D cluster symptoms).
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3.3. Estradiol and stress reactivity
Levels of the salivary stress biomarkers alpha amylase and cortisol across the laboratory
visit are presented in Table 3. Pre-stressor (study baseline) cortisol (M = 0.17, SD = 0.09, range:
0.06 - 0.49) and alpha amylase (M = 43.80, SD = 35.19, range: 6.72-159.99) values were
normally distributed with no outliers. We conducted non-parametric paired-samples tests
(Wilcoxon signed-rank test) to test differences in alpha amylase and cortisol from the study
baseline to the trauma reminder. Overall, participants showed an increase (Mean percent change
= 55.97% (SD = 112.92), range: -65.92% to 470.38%) in alpha amylase from the study baseline
to the trauma reminder, Z = 2.65, p = 0.008, r = 0.41. Overall, cortisol levels did not increase in
response to the trauma reminder (Mean percent change = -4.08% (SD = 42.52), range: -73.42%
to 165.08%), but rather decreased, Z = -2.07, p = 0.038, r = -0.33 (see Figure 6).
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Figure 6. Stress reactivity to the trauma reminder. Participants showed an increase in alpha
amylase (AA) from the study baseline (T1) to the trauma reminder. Conversely, cortisol levels
decreased from the study baseline (T2) to the trauma reminder. Error bars represent standard
errors.
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We used Pearson product-moment correlations to test associations between estradiol
levels on the morning of the laboratory visit and reactivity in the two stress systems in the entire
sample. Estradiol was not associated with alpha amylase, r = 0.038, p = 0.814, or cortisol
reactivity, r = -0.026, p = 0.872, to the trauma reminder.
Due to variation in menstrual cycle phase during the laboratory visit, we also tested
sympathetic and HPA axis reactivity by cycle phase. We separated the data into two group
categories based on lab visit day cycle phase: low estradiol phases (early follicular, early luteal,
late luteal) or high estradiol phases (late follicular/peri-ovulatory, mid-luteal). Wilcoxon ranksum tests comparing participants in low versus high estradiol phases of the cycle indicated group
differences in stress reactivity. Compared with participants in high estradiol phases (n = 23),
participants in low estradiol phases (n = 17) had greater alpha amylase reactivity, Z = -2.05, p =
0.040, r = -0.32, but lower cortisol reactivity, Z = 2.74, p = 0.006, r = 0.43, to the trauma
reminder (see Figure 7).
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Figure 7. Stress reactivity by menstrual cycle phase. Participants in low versus high estradiol
(E2) phases of the menstrual cycle showed greater SNS reactivity, indexed via percent change in
salivary alpha amylase (AA), and reduced HPA axis reactivity, indexed via percent change in
salivary cortisol, to the trauma reminder. Error bars represent standard errors.
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3.4. Ecological momentary assessment protocol compliance
Participant compliance with the ecological momentary assessment (EMA) protocol is
outlined in Table 6. Six participants had missing or insufficient EMA questionnaire data (more
than 50% of day forms missing or completed at times inconsistent with the prompts) and were
therefore excluded from these analyses. The remaining sample showed high compliance with the
protocols.
Table 6. Participant compliance with EMA protocol
Form type

% Complete

Morning forms

98.5%

Daytime forms

84.9%

Daytime forms within 30 mins

71.4%

Evening forms

96.7%

3.5. Phase differences in affect
We conducted paired samples t-tests to test differences in self-reported affect during the
EMA portion of the study by menstrual cycle phase. Overall valence ratings, t(29) = -0.22, p =
0.824, d = -0.03, and arousal ratings, t(29) = 0.27, p = 0.792, d = 0.03, did not differ by
menstrual cycle phase. However, the variability of affect ratings, indexed via standard
deviations, varied by phase, such that standard deviations for valence ratings, t(29) = 3.11, p =
0.004, d = 0.49, and arousal ratings, t(29) = 2.41, p = 0.022, d = 0.35, were higher during the
early versus late follicular phase. Additionally, the strongest effect of cycle phase was on the
percentage of timepoints in which participants reported experiencing unpleasant high arousal
states (defined as valence <5 and arousal >5). The percentage of self-reported aversive affective
experiences was higher during the early versus late follicular phase, t(29) = 3.20, p = 0.003, d =
0.82 (see Figure 8).
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Figure 8. Affect by cycle phase. Mean valence and arousal ratings did not differ by menstrual
cycle phase (Panel A). However, participants showed greater variability in valence and arousal
ratings during the early versus late follicular phase (Panel B). Additionally, during the early
versus late follicular phase, participants reported greater number of unpleasant (negatively
valenced) high arousal affective states (Panel C). Error bars represent standard errors.
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Positive and negative affective states, indexed by scores on the Positive and Negative
Affect Schedule (PANAS), also differed by cycle phase (see Figure 9), but only on evening
assessments. Positive and negative affect reported on the morning assessments did not differ by
cycle phase (Morning positive affect scores: t(29) = 1.64, p = 0.112, d = 0.25; Morning negative
affect scores: t(29) = -0.14, p = 0.890, d = -0.019). On the evening assessments, participants
reported greater negative affect during the early versus late follicular phase at the trend level,
t(29) = 2.02, p = 0.052, d = 0.28. Participants also reported greater positive affect on the evening
assessments, t(29) = 2.51, p = 0.018, d = 0.32.
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Figure 9. Positive and negative affective states by cycle phase. Self-reported positive and
negative affective reported on morning assessments did not differ by cycle phase. However, on
evening assessments, participants reported greater negative affect at the trend level and greater
positive affect during the early versus late follicular phase. Error bars represent standard errors.
3.6. Phase differences in trauma-related symptoms
We conducted non-parametric paired-samples tests (Wilcoxon signed-rank tests) to test
differences in self-reported daily PTSD symptoms by cycle phase. Participants reported greater
overall symptom severity during the early versus late follicular phase, Z = 2.28, p = 0.023, r =
0.30. Additionally, participants reported greater severity of negative alterations in cognitions and
mood (D cluster) symptoms, Z = 2.40, p = 0.016, r = 0.31 and arousal (E cluster) symptoms, Z =
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1.86, p = 0.063, r = 0.24, during the early versus late follicular phase. Self-reported reexperiencing (B cluster), Z = 1.54, p = 0.125, r = 0.20, and avoidance (C cluster), Z = 0.60, p =
0.547, r = 0.08, symptom severity did not differ by cycle phase (see Figure 10).
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Figure 10. PTSD symptoms by cycle phase. During the early versus late follicular phase,
participants reported greater total severity of PTSD symptoms, as well as greater severity of
negative alterations in cognitions and mood (D cluster) symptoms and a trend toward greater
arousal (E cluster) symptoms. Error bars represent standard errors.

3.7. Hormone fluctuations and daily affect
We tested Pearson correlations between the magnitude of estradiol increase from the
early to late follicular phase (over the course of the 10-day EMA period) and self-reported affect
for the duration of the EMA protocol and within each cycle phase. Increase in estradiol was not
associated with overall valence, r = 0.18, p = 0.332, or arousal ratings, r = 0.05, p = 0.796, across
the EMA period. However, increase in estradiol was associated at the trend level with greater
variability in arousal, as indexed by standard deviation of arousal ratings, r = 0.34, p = 0.063.
When we tested the association between estradiol increase and valence ratings within each cycle
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phase, the strongest association between estradiol increase and standard deviation of arousal
ratings was during the early follicular phase, r = 0.36, p = 0.048. Estradiol increase was also
associated at the trend level with standard deviation of arousal ratings during the late follicular
phase, r = 0.32, p = 0.086. Estradiol increase was not associated with self-reported PTSD
symptoms during the EMA period (all p-values > 0.05).

3.8. Lifestyle factors by cycle phase
In addition to daily affect, participants also reported on sleep quality, exercise and
substance use across the ten day EMA phase. Participant report of hours slept per night did not
differ by menstrual cycle phase, t(29) = 1.45, p = 0.158. Participants reported relatively little
exercise during the ten days, averaging less than one session during both the early follicular and
late follicular phases. Exercise did not differ by cycle phase, t(29) = 1.22, p = 0.234. Our
participants reported extremely low rates of alcohol and other substance abuse, with most
participants reporting no consumption at any time, precluding a comparison of substance use by
cycle phase.

4. Discussion
The overall goal of this dissertation was to test the effect of estradiol on daily affective
experiences, including trauma-related symptoms. We addressed this goal using a multi-method
approach, including cross-sectional and ecological momentary assessment (EMA) techniques, to
examine stress reactivity in response to a trauma reminder and daily affect across low and high
estradiol phases of the menstrual cycle. Despite well-established increased risk for severe and
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persistent symptoms following trauma in women compared to men (e.g., Breslau et al., 2002;
Haskell et al., 2010; Seedat et al., 2005) and well-established differences in affective and stressrelevant neural circuitry (e.g., Mareckova et al., 2016; Kajante & Phillips, 2006; Wrase et al.,
2003), most of our current knowledge of PTSD has come from studies examining men or male
animals. A better understanding of hormone fluctuations unique to women could explain
increased symptom vulnerability and could inform treatment tailoring.
The previous literature on this topic is mostly divided into two main areas: research on
menstrual cycle variability in stress and affect, and research on the effects of estradiol on indices
of maladaptive fear, such as impaired fear extinction and intrusive memories, that are associated
with risk for PTSD symptoms. Given the reported associations between low estradiol and
mechanisms underlying increased risk for PTSD symptoms (e.g., impaired extinction; Graham &
Milad, 2013), it follows that trauma-exposed women might be more prone to symptoms at low
estradiol phases of the cycle. To date, however, very few studies (e.g., Nillni et al., 2015) have
tested the effect of estradiol or menstrual cycle phase on affective experiences in trauma-exposed
populations. Additionally, most previous studies of menstrual cycle variability in stress or affect
have relied on data from a small number of laboratory sessions, or focused on comparisons
between the early follicular and mid-luteal phases. However, high levels of both estradiol and
progesterone characterize the mid-luteal phase, and progesterone is known to influence
cognition, affect and psychological symptoms (e.g., Ertman, Andreano, & Cahill; Klump et al.,
2013). Given this potential confound, previous research precludes definitive conclusions
regarding the unique effects of estradiol on affective experiences. To address these gaps in the
literature, we examined PTSD symptoms during a laboratory visit and over the course of a tenday EMA procedure that spanned the early follicular and late follicular phases. This EMA design
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allowed us to examine a portion of the menstrual cycle characterized by increases in estradiol,
with minimal influence of progesterone. We verified appropriate menstrual cycle phase by
measuring gonadal hormone levels, and confirmed that all participants’ progesterone levels
remained within the normative range for the follicular phase. During the laboratory visit, we also
tested associations between estradiol and physiological stress reactivity to a naturalistic trauma
reminder.
Consistent with our first hypothesis, estradiol levels during the laboratory visit were
associated with greater severity of PTSD symptoms reported during the clinical interview. This
association was driven by re-experiencing, avoidance and arousal symptoms, with no association
between estradiol and negative alterations in cognitions and mood. Increased report of symptoms
associated with lower estradiol adds to the existing evidence for a protective effect of estradiol
on intrusive thoughts and memories (re-experiencing symptoms) (e.g., Soni et al., 2013; Wegerer
et al., 2014). Our data also suggest that during lower estradiol phases of the menstrual cycle,
trauma-exposed women are more prone to cognitive and behavioral avoidance of trauma-related
information and arousal symptoms, such as irritability, difficulty sleeping, exaggerated startle
response, risky behaviors and hypervigilance for threat.
We also demonstrate differences in stress reactivity by menstrual cycle phase. Consistent
with previous work in trauma-exposed populations (e.g., Carpenter et al., 2011), our sample as a
whole showed SNS reactivity, but blunted HPA axis reactivity, in response to a trauma reminder.
Inconsistent with our second hypothesis, however, individual variation in estradiol was not
associated with physiological stress reactivity to a trauma reminder. This result was somewhat
surprising, given the association between estradiol and self-reported arousal symptoms.
However, when we divided the sample into two groups according to menstrual cycle phase
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during the interview, group differences emerged, such that participants in lower estradiol phases
(i.e., early follicular, early luteal, late luteal) had greater sympathetic and lower HPA axis stress
reactivity compared to those in higher estradiol phases (i.e., late follicular/mid-cycle, mid-luteal).
These data are consistent with evidence linking the stress response profile of higher SNS and
lower HPA axis activity with greater affective symptoms in trauma-exposed populations (e.g.,
Ali & Pruessner, 2012).
The association between estradiol and arousal symptoms along with the absence of an
association between estradiol and stress reactivity underscore the non-redundancy of self-report
and physiological measures. Self-reported distress associated with lower estradiol was not
explained by objective physiological differences in stress system function. Instead, estradiol
levels at the time of assessment might influence current affective state, coloring perception of
trauma-related symptoms and related distress over the past month. This interpretation is
consistent with evidence for biased retrospective reports of affect (e.g., Ben-Zeev, Young, &
Madsen, 2009; Mill et al., 2016) and physical symptoms (e.g., Brown & Moskowitz, 1997) in
healthy people and clinical populations. Alternatively, differential stress reactivity in high
compared to low estradiol menstrual cycle phases might speak to the importance of withinperson estradiol fluctuations, in addition to individual differences. Previous evidence for the
influence of estradiol on stress reactivity (e.g., Kajante & Phillips, 2006; Kirschbaum et al.,
1999) could have been due to the absolute magnitude of estradiol levels, which differ by phase,
or due to within-person increases and decreases in estradiol across the menstrual cycle. Our
results provide stronger evidence for the latter in a non-clinical sample of naturally cycling
young women with regular menstrual cycles.
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Consistent with an effect of estradiol fluctuations on affect, and in line with our third
hypothesis, daily affective experiences differed by menstrual cycle phase. Self-reported affect
was more variable, indicating greater affective lability, during the early follicular (low estradiol)
compared to late follicular (high estradiol) phase. In addition, during the early follicular phase,
participants reported more frequent aversive affective experiences, falling within the unpleasant,
high arousal quadrant of the affective circumplex. This quadrant includes affective states that can
be highly distressing and potentially interfere with daily life function. These data suggest that
affective lability during low estradiol phases might contribute to greater subjective distress,
which is consistent with evidence demonstrating that affective variability contributes to negative
affect (e.g., Wichers et al., 2010).
In addition to self-reported affect, daily total PTSD symptom severity was also greater
during the early versus late follicular phase. This effect was driven by two symptom clusters:
arousal symptoms and negative alterations in cognitions and mood. The arousal symptom cluster
encompasses heightened physiological arousal, both tonically and in response to external stimuli
(e.g., exaggerated startle response), whereas negative alterations in cognitions and mood
encompasses persistent negative affect as well as negative cognitions, such as inappropriate selfblame and exaggerated negative beliefs (e.g., about the self, other people or the world). These
data are consistent with evidence for poorer psychological well-being (e.g., Kanojia et al., 2013;
Nillni et al., 2015) and increased physiological arousal (e.g., Kanojia et al., 2013) during low
estradiol phases of the cycle. To our knowledge, this is the first study to demonstrate greater
negative cognitions in trauma-exposed women during a low compared to high estradiol phase.
Finally, during the early follicular phase, participants more strongly endorsed both
negative and positive affective states, although this effect only applied to evening reports.
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Evening reporting of greater positive and negative affect provides additional evidence for more
variable, rather than strictly negative, affect during low estradiol states. Morning reports of affect
did not differ by cycle phase, underscoring the influence of time of day on self-reported affective
experiences. Compared to morning reporting, evening reporting of daily affect was more
sensitive to differences by menstrual cycle phase.
Our exploratory analysis of hormone fluctuations and daily affect revealed that greater
estradiol increase from the early to late follicular phase was associated with greater variability in
self-reported arousal across the EMA phase of the study. This association was strongest during
the early follicular (low estradiol) phase. We speculate that greater variability in estradiol across
the menstrual cycle might be associated with increased risk for affective instability during low
estradiol cycle phases.
Overall, our data speak to the importance of estradiol fluctuations on daily affective
experiences in trauma-exposed women. Further, given that we controlled for progesterone, we
demonstrate unique effects of estradiol on daily affect. Our data suggest that estradiol buffers
against negative affect and stress-related symptoms and is associated with more stable affect.
Variation in daily affect associated with estradiol might reflect an evolutionary advantage.
Greater symptoms of negative affect during lower estradiol portions of the cycle, particularly the
late luteal phase, might have rendered women more withdrawn and cautious, potentially
adaptive behaviors when a woman has become pregnant. Conversely, high estradiol levels and
the associated mood buffer might have encouraged women to seek reproductive opportunities
during the most fertile portion of the menstrual cycle. In a modern context, however, menstrual
variation in mood might render women more susceptible to stress-related symptoms.
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Fluctuations in daily affect could have particular implications for clinical populations.
Client report of more trauma-related symptoms during low compared to high estradiol phases
could influence diagnostic status or PTSD severity. Clinicians might therefore improve
diagnostic accuracy by accounting for client menstrual cycle phase at the time of assessment. To
maximize sensitivity to clients’ symptoms, clinicians might schedule assessments during low
estradiol phases of the cycle.
Greater knowledge of menstrual cycle variability in affect can also inform treatment.
Clinicians who work with PTSD populations could gather information about clients’ recent
menstrual cycles to predict when clients will experience more frequent aversive daily
experiences, including symptoms. Clinicians can also potentially tailor treatments and schedule
interventions at specific points in the menstrual cycle.
Finally, the relation between lower estradiol and increased report of re-experiencing,
avoidance and arousal symptoms suggests that individual differences in estradiol might influence
risk for symptoms post-trauma. Identifying women at increased risk for symptoms due to low
estradiol levels could enhance preventative interventions post-trauma.

5. Limitations and future directions
We demonstrate a profile of increased sympathetic and blunted HPA axis reactivity to a
naturalistic trauma reminder during a low versus high estradiol phase. Differential stress
reactivity by cycle phase suggests that estradiol fluctuations influence the coordination of stress
system function. We interpret the absence of a relationship between estradiol and physiological
stress reactivity as evidence for a stronger effect of estradiol fluctuations, rather than absolute
estradiol levels, on stress reactivity in trauma-exposed women. However our interpretation is
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somewhat limited by the fact that we were not able to directly test the effect of cycle phase on
stress reactivity since we did not pre-assign lab visit timing based on cycle phase. To better
address this issue, researchers might assess all participants during a specific cycle phase and
subsequently test associations between estradiol and stress reactivity.
Additionally, all of our participants had gonadal hormone levels within normative ranges.
The relation between estradiol and stress reactivity might be different in women with abnormally
high or low hormone levels, menstrual cycle irregularities or endocrine disorders. Our results
should be replicated in these populations. In these populations, the absolute magnitude of
estradiol might have a stronger influence on stress reactivity.
Our data suggest more frequent aversive affective experiences and increased PTSD
symptom severity during low compared to high estradiol menstrual cycle phases. We also report
greater affective lability, indexed by the standard deviation of participant arousal ratings across
the 50 daily timepoints, during the early follicular phase. However, our data analyses cannot
provide information about specific patterns of affective instability. For example, we cannot
determine whether increased variability was driven by greater within-day fluctuations or by
greater day to day differences in affect across the early follicular phase. A more nuanced
understanding of the patterns of affective variability would require replication of our study with a
much larger sample, which would provide adequate statistical power for multilevel modeling
analyses.
In addition, our ecological momentary assessment results should be replicated in clinical
populations with PTSD. Our sample consisted of high-functioning trauma-exposed women, most
of whom did not meet criteria for PTSD. A subset of participants met criteria for a provisional
diagnosis of PTSD, but scored on the low end of the severity range. We speculate that our

53
observed differences in affect by menstrual cycle phase, which were detectable in highfunctioning trauma-exposed women, would be more evident in clinical populations. However, it
is possible that women with PTSD experience symptoms more consistently across the cycle, with
no alleviation of symptoms during high estradiol phases.
Our results should also be replicated in trauma-exposed samples with specific trauma
types, as the relation between estradiol and symptoms could differ by trauma type. Survivors of
interpersonal compared to non-interpersonal trauma tend to report more PTSD symptoms (e.g.,
Luthra et al., 2009), especially negative cognitions (Kirkpatrick et al., 1989), which differed by
menstrual cycle phase in our sample. Thus, the protective effect of estradiol on these particular
symptoms might therefore be especially relevant for survivors of interpersonal trauma or for
survivors of specific index traumas (e.g., sexual trauma). Due to our small numbers of
participants reporting non-interpersonal trauma, and the heterogeneity in exposure to specific
index traumas, we did not have adequate statistical power to test differences in the relation
between estradiol and stress reactivity or affect by trauma type.
In addition to trauma type, age at trauma is another potential moderator of the relations
among estradiol, stress reactivity, and symptoms. Existing evidence suggests that stress system
function following trauma and its relation with symptoms varies as function of the time since
trauma, such that blunted activity as (e.g., Weems & Carrion, 2007). Further, developmental
stage at the time of trauma exposure can influence subsequent effects on brain development and
vulnerability for symptoms (e.g., Andersen et al., 2008; Bick & Nelson, 2016; Sullivan et al.,
2006). In our sample, time since trauma was not associated with cortisol (r = -0.84, p = 0.61) or
alpha amylase (r = 0.18, p = 0.27) reactivity to the naturalistic stressor. However, larger sample
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sizes would provide sufficient power to test trauma timing as a mediator or moderator of our
reported effects.
Finally, although we interpret our data as evidence for greater negative affect and
affective lability during low estradiol phases, differences between the early and late follicular
phases could reflect biases in self-report as a function of time. There could be potential order
effects, given that we could not counterbalance the early follicular phase (first five EMA days)
and late follicular phase (last five EMA days). Recent evidence also suggests an “attenuation
effect” in studies with experience sampling methods, whereby participants show initial
elevations in reports of affective experiences, especially negative affective states, at the
beginning of an assessment period (Shrout et al., 2018). The attenuation effect is generally
strongest for initial assessment timepoints, with smaller effects for later timepoints on the initial
day of assessment and no effects past the initial assessment day (Shrout et al., 2018). Given that
our EMA data collapses across the entire early and late follicular phases (five days each), we
suggest that any attenuation effects would have little impact on our results. Additionally, our
results highlight greater affective lability, rather than simply increased reporting of negative
affective states, during the early compared to late follicular phase.

Conclusions
The current dissertation makes a novel contribution to the literature on estradiol and
affect by tracking momentary affect and daily symptoms across low and high estradiol menstrual
cycle phases, rather than relying on single-timepoint retrospective reports, and by controlling for
the influence of progesterone. Additionally, by demonstrating increased sympathetic and
decreased stress reactivity during low versus high estradiol phases, the current study underscores
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the importance of estradiol and menstrual cycle phase for research on stress reactivity in traumaexposed women.
Our data contribute to our understanding of how fluctuations in sex hormones potentially
contribute to risk for post-trauma symptoms. We demonstrate differential stress reactivity by
menstrual cycle phase, whereby trauma-exposed women showed a profile of greater sympathetic
but lower HPA axis activity to trauma reminders during a low compared to high estradiol phase.
We propose that this profile of asymmetrical stress system response is a potential mechanism
underlying greater risk for symptoms during low estradiol phases.
Our data add to the existing evidence for menstrual cycle variability in psychological
symptoms (e.g., Edler et al., 2007; Gonda et al., 2008; Kanojia et al., 2013; Walder et al., 2012).
We additionally address a gap in the literature and demonstrate that daily affective experiences
differ between low and high estradiol phases, while progesterone remains low. We demonstrate
more frequent reporting of aversive affective experiences and greater affective lability during a
low compared to high estradiol phase. We suggest that trauma exposed women are more likely to
experience PTSD symptoms during lower estradiol phases and speculate that this effect might be
more evident in clinical PTSD populations. These data contribute to our understanding of
changes in hormones that influence patterns of symptoms in women, and have the potential to
inform treatment tailoring.
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